Identification of pyrazolo-pyrimidinones as GHS-R1a antagonists and inverse agonists for the treatment of obesity
MedChemComm2012Vol. 4(2), pp. 456–456
Citations Over TimeTop 22% of 2012 papers
William McCoull, Peter Barton, Anders Broo, Alastair Brown, David S. Clarke, Gareth Coope, Robert D. M. Davies, Alexander G. Dossetter, Elizabeth E. Kelly, Laurent Knerr, Philip A. MacFaul, J. L. Holmes, Nathaniel G. Martin, Jane E. Moore, David Morgan, Claire Newton, Krister Österlund, Graeme R. Robb, Eleanor Rosevere, Nidhal Selmi, S.P. Stokes, Tor Svensson, Victoria Ullah, Emma Williams
Abstract
A pyrazolo-pyrimidinone based series of growth hormone secretagogue receptor type 1a (GHS-R1a) antagonists and inverse agonists were identified using a scaffold hop from known quinazolinone GHS-R1a modulators. Lipophilicity was reduced to decrease hERG activity while maintaining GHS-R1a affinity. SAR exploration of a piperidine substituent was used to identify small cyclic groups as a functional switch from partial agonists to neutral antagonists and inverse agonists. A tool compound was identified which had good overall properties and sufficient oral plasma and CNS exposure to demonstrate reduced food intake in mice through a mechanism involving GHS-R1a.
Related Papers
- → Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy(2016)19 cited
- → Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death(2013)10 cited
- → Time is a critical factor in evaluating indirect hERG inhibition by Oligonucleotide Therapeutics(2022)
- → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)